Reasons for Jonathan Johnson’s Shares Sale of, Inc. (OSTK)’s Stock; Exact Sciences (EXAS) Has 1.01 Sentiment

Considering the deal Jonathan Johnson made he is in the insider trading spotlight today. The President – Medici of Overstock.Com Inc and an insider, made a sale of 4,000 shares worth $264,400 US Dollars. The average price was $66.1 per share. Jonathan Johnson now has in hand 34,087 shares of the Company. Dated February 5, 2018, this sudden deal by Jonathan Johnson was disclosed inside a legal document submitted with the Washington-based SEC. It is free at your disposal for review here.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company has market cap of $5.86 billion. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer. It currently has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

Since August 9, 2017, it had 0 insider purchases, and 4 insider sales for $711,061 activity. $120,400 worth of, Inc. (NASDAQ:OSTK) was sold by JOHNSON JONATHAN E III on Monday, October 2. Lee Carter Paul had sold 2,000 shares worth $37,015.

The stock decreased 6.87% or $3.85 during the last trading session, reaching $52.15. About 3.36M shares traded., Inc. (NASDAQ:OSTK) has declined 7.99% since February 5, 2017 and is downtrending. It has underperformed by 24.69% the S&P500., Inc. operates as an online retailer in the United States. The company has market cap of $1.31 billion. The firm operates through two divisions, Direct and Partner. It currently has negative earnings. It offers brand name, non-brand name, and closeout products, including furniture, home decor, bedding and bath, housewares, jewelry and watches, apparel and designer accessories, health and beauty products, electronics and computers, and sporting goods, among other products; and sells various books, magazines, CDs, DVDs, and video games.

Among 2 analysts covering (NASDAQ:OSTK), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. has $85 highest and $20 lowest target. $54’s average target is 3.55% above currents $52.15 stock price. had 5 analyst reports since May 26, 2016 according to SRatingsIntel. On Wednesday, February 1 the stock rating was maintained by Maxim Group with “Buy”. Maxim Group initiated the shares of OSTK in report on Thursday, May 26 with “Buy” rating. DA Davidson maintained the stock with “Buy” rating in Friday, December 1 report. The firm has “Buy” rating by DA Davidson given on Wednesday, September 6. The rating was maintained by DA Davidson on Thursday, November 9 with “Buy”.

Investors sentiment increased to 1.77 in 2017 Q3. Its up 0.35, from 1.42 in 2017Q2. It increased, as 13 investors sold, Inc. shares while 18 reduced holdings. 26 funds opened positions while 29 raised stakes. 11.11 million shares or 5.86% more from 10.49 million shares in 2017Q2 were reported. Park West Asset Mngmt Limited Liability holds 900,000 shares. Moreover, Chou Associate Inc has 2.97% invested in, Inc. (NASDAQ:OSTK). Sanctuary Wealth Lc accumulated 326 shares or 0.01% of the stock. Rhumbline Advisers holds 20,174 shares or 0% of its portfolio. 120,662 are owned by Tiaa Cref Investment Management Ltd Company. Millennium Mngmt Ltd holds 0% or 7,995 shares in its portfolio. Jane Street Ltd Liability owns 26,525 shares for 0% of their portfolio. Dimensional Fund Advisors Lp reported 1.63 million shares or 0.02% of all its holdings. Vanguard Gp invested 0% of its portfolio in, Inc. (NASDAQ:OSTK). Legal & General Pcl reported 4,856 shares stake. Polar Asset Mgmt Ptnrs holds 0.09% or 147,910 shares. California State Teachers Retirement Sys owns 26,774 shares. Susquehanna Intll Gp Limited Liability Partnership has invested 0% in, Inc. (NASDAQ:OSTK). Parametric Assocs reported 19,434 shares. Deutsche Retail Bank Ag holds 16,346 shares or 0% of its portfolio.

Ratings analysis reveals 33% of EXACT Sciences’s analysts are positive. Out of 3 Wall Street analysts rating EXACT Sciences, 1 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $15.0 while the high is $17.0. The stock’s average target of $16 is -67.28% below today’s ($48.9) share price. EXAS was included in 3 notes of analysts from October 26, 2016. The stock has “Hold” rating by Lake Street on Tuesday, November 1. Benchmark maintained Exact Sciences Corporation (NASDAQ:EXAS) on Wednesday, October 26 with “Hold” rating. The rating was upgraded by Roth Capital on Wednesday, February 22 to “Buy”.

The stock decreased 0.20% or $0.1 during the last trading session, reaching $48.9. About 1.31 million shares traded. Exact Sciences Corporation (EXAS) has risen 458.24% since February 5, 2017 and is uptrending. It has outperformed by 441.54% the S&P500.

Analysts await Exact Sciences Corporation (NASDAQ:EXAS) to report earnings on February, 20. They expect $-0.29 earnings per share, up 14.71% or $0.05 from last year’s $-0.34 per share. After $-0.23 actual earnings per share reported by Exact Sciences Corporation for the previous quarter, Wall Street now forecasts 26.09% negative EPS growth.

Since January 1, 0001, it had 0 insider buys, and 7 insider sales for $22.47 million activity.

Antipodean Advisors Llc holds 22.96% of its portfolio in Exact Sciences Corporation for 577,346 shares. Zevenbergen Capital Investments Llc owns 2.12 million shares or 4.33% of their US portfolio. Moreover, Sanctuary Wealth Advisors Llc has 3.18% invested in the company for 87,180 shares. The Wisconsin-based Thompson Investment Management Inc. has invested 2.4% in the stock. Elk Creek Partners Llc, a Colorado-based fund reported 762,288 shares.